spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed Using Nouscom’s Proprietary Viral Vector Platform

Nouscom

VAC85135 is a novel clinical candidate developed by Nouscom and Janssen under a multi-project agreement


BASEL, Switzerland – 17th May 2022
- Nouscom, a clinical stage immuno-oncology company developing both off-the-shelf and personalized cancer neoantigen immunotherapies, today announced that Janssen Research & Development, LLC (Janssen) received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) candidate VAC85135, an off-the-shelf, viral vector-based cancer vaccine for an oncologic indication. VAC85135 has been exclusively licensed to Janssen.

VAC85135 is based on Nouscom’s proprietary viral vector platform and is the first vaccine candidate to advance to this stage under a multi-project agreement with Janssen. Nouscom and Janssen have collaborated on the design and specific product research, with Nouscom accountable for process development activities and GMP manufacturing for VAC85135.

Under the terms of the agreement, Janssen has sole responsibility for clinical development of VAC85135. Financial terms, including individual product-specific upfront payments, potential development and commercial milestones, and future tiered royalties remain confidential.

Dr. Marina Udier, Chief Executive Officer of Nouscom, said, “We are very excited about Janssen’s IND clearance of VAC85135, the result of a long-standing and productive collaboration. This is another important milestone for Nouscom, the first licensed program, and the third clinical candidate after NOUS-209 and NOUS-PEV, to emerge from our immunologically potent viral vector platform”.
phone +41 61 201 18 31
email info@nouscom.com
web www.nouscom.com/
email Bäumleingasse, 18 CH-4051 Basel
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility

TOKYO, November 22, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will be operated by FUJIFILM Irvine Scientific, Inc., a subsidiary of FUJIFILM Corporation, and a world leader in the development and manufacture of advanced cell culture solutions for life science research, bioproduction, cell therapy manufacturing, and medical applications. The new facility is planned to ensure that FUJIFILM Irvine Scientific can meet increasing market demands for high quality cell culture media solutions.
More info >>


White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement